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1. ABBREVIATIONS 
 
6-MAM 6-monoacetylmorphine 
A amphetamines  
BDZ benzodiazepines 
BMI body mass index 
CdS Codice della Strada (Road Code) 
C.M.L Local Medical Commission 
CNS Central Nervous System 
DUI driving under influence 
EDDP 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine 
GC-MS Gas Chromatography-Mass Spectrometry 
GTFI Group of Italian Forensic Toxicologists 
m/z mass-to-charge ratio 
MA methamphetamine,  
MBDB N-methyl-1-(1,3-benzodioxol-5yl)-2-butamine  
MDA 3,4-methylenedioxyamphetamine 
MDE methylenedioxyetamphetamine   
MDMA 3,4-methylenedioxymethamphetamine  
MSTFA N-methyl-N-trimethylsilyl-trifluoroacetamide 
SIM Selected Ion Monitoring 
SPE solid-phase extaction 
Δ9-THC Δ9-tetrahydrocannabinol 
Δ9-THC-COOH 11-nor-9-carboxy-Δ9-tetrahydrocannabinol 
 
 
Abstract 
2 
 
2. ABSTRACT 
 
Background and goals: According to the Italian Road Code, driving under the 
influence of drugs is forbidden and the violation of this rule is sanctioned with, among 
others, the withdrawal or the revocation of the driving license. In order to have his/her 
license back, the sanctioned individual is submitted to a clinical examination aimed at 
evaluating his/her fitness to drive, including analysis for drugs of abuse in urine and/or 
in hair. A positive result to these tests implies a diagnosis of non-fitness to drive for a 
given time period (typically 6 months to 1 year) after which the individual may reapply 
for driving license. This research project is aimed at providing an insight in the data 
collected by the toxicology laboratory of the Legal Medicine Unit of the Department of 
Medicine & Public Health over the years concerning urine and/or hair analysis for drugs 
of abuse for the evaluation of the fitness to drive with the purposes of (i), defining 
trends in drug abuse, and identifying specific risk factors for drug abuse and relapse in 
drug abuse in the observed population, (ii) selecting the most effective and efficient 
analytical strategy to detect drug abuse. 
Methods: Analysis for drugs of abuse either in urine or in hair was carried out in the 
laboratory using a combined analytical approach: immunochemical screening for 
opiates, cocaine, amphetamines and derivatives (urine and hair) and cannabinoids, 
benzodiazepines and barbiturates (urine only) and GC-MS confirmation of positives. 
The following screening cut-offs were applied: 500 ng/ml for amphetamines and 
derivatives, 300 ng/ml for opiates, methadone and cocaine, 200 ng/ml for 
benzodiazepines and barbiturates, 50 ng/ml for cannabinoids in urine; 0.1 ng/mg for all 
analytes in hair. 
Hair analysis was carried out on one hair sample (3-4 cm proximal segment in order to 
infer on the history of drug use during the 3-4 month period preceding sample 
collection) collected at the beginning of the sampling protocol. In the case of baldness 
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or when hair appeared to have been submitted to strong cosmetic treatments (e.g. 
bleaching, perming), pubic hair was collected instead. In the case of urine, different 
sampling protocols were applied: 3 urine samples randomly collected without notice to 
the subject within a 4-week period or 8 urine samples collected at pre-defined times 
with notice to the patient within the same period of time. The biological substrate (urine 
and/or hair) and the urine sampling protocol were established by the Medical 
Commission in charge of evaluating driving fitness on the basis of the clinical records 
of the subject. 
Personal as well as clinical and anamnestic data on the individuals undergoing urine 
and/or hair testing were recorded together with test results in a database constructed 
using Microsoft Access (2003 version). Statistical analysis on the cases examined 
during 2003 and 2008 (981 cases) was carried out using Microsoft Excel (2003 
version). 
Results: In the period under study, the total number of subjects who underwent driving 
fitness diagnosis was 981. 24% (n=231) of them tested positive, 49% (n=483) were 
negative and 27% (n=267) didn’t show up after being called upon for clinical 
examination and samples collection. 
Cocaine (n=124, 17%), was the drug most frequently detected, followed by 
cannabinoids (n=86, 12%), benzodiazepines (n=42, 6%), opiates (n=22, 3%), 
amphetamines and derivatives (n=21, 3%), methadone (n=11, 2%) and barbiturates 
(n=5, 1%). Thirty percent of the subjects who tested positives, were positives for more 
the one drug class, and one of these was usually cocaine. 
The subjects analyzed were mostly men 93% (n=907). The mean age was 31 (range 
18-63) and was the same for positives and negatives. Nevertheless, different mean 
ages were observed among subjects testing positive for different drug classes: younger 
subjects, with a mean age of 23 years, seem to have a higher risk to use 
amphetamines while older subjects, with a mean age of 35/36 years, test more 
frequently positive for benzodiazepines and barbiturates.  
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Smokers and subjects with an anamnesis for alcohol-abuse were more represented 
among positives, however the difference was not statistically significant probably due to 
the relatively small number of cases. 
Generally, an increase of BMI with age was observed among positive and negative 
subjects. However a different BMI trend was found out in subjects testing positive for 
different drug classes. In opiates and amphetamines users the increase of BMI with 
age was more marked then in negatives. For cocaine and benzodiazepines users, the 
BMI trend was approximately the same of negatives. Furthermore, a peculiar BMI trend 
in cannabinoids users was observed: in the first two age ranges (18-25 and 26-35 
years) the trend was similar to negatives but in the last range (36-45 years) a decrease 
with respect to negatives was observed. 
The toxicological anamnesis of the subjects appeared to be very informative. In fact, 
thirty percent of the subjects who reported a previous use of a specific drug, tested 
actually positive for that substance. In addition, the probability to find a positive subject 
for any substances increased when he/she declared a previous use of cocaine. 
The comparison between hair and urine analysis for cocaine, opiates and 
amphetamines showed the complementary features of these two matrices. In fact, 
there were subjects testing positive in hair and negative in urine and viceversa. 
Part of the research was dedicated to assessing the possible correlation between our 
results and the numbers of road accidents occurred on the provincial area. In general, 
a positive but weak correlation between the percentage of subjects testing positive for 
different drugs and the frequency of road accidents within the same year (no. road 
accidents/number of cars in the province of Verona). According to the Italian road code, 
after a car accident where drug use was ascertained, the subject has to undergo a 
clinical examination to test his fitness to drive (Art. 119), so one could argue that these 
positive trends may be due to the fact that if the number of accidents increases, also 
the clinical examinations should increase. However, during the studied period, no 
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positive trend between the absolute number of traffic accidents and number of clinical 
examination requested was observed (Art. 119). 
The comparison between results of the first and second check (which is mandatory for 
both negative and positive subjects after a variable period of time, typically 6-12 
months) has shown that only 27% of positives at the first check were still positive at the 
second but also that 9% of negatives at the first check were positive at the second.  
Conclusion: The percentage of positives at the first check was 24%, increasing to 
32% excluding subjects who didn’t show up for the clinical examination. 
Cocaine was the most frequently detected illicit drug and was commonly found with 
other illicit substances. The majority of subjects involved in the study were males (93%) 
and the same percentage was discovered among positives. Different mean ages were 
observed in users of different substances: younger age appeared to be more frequently 
associated to amphetamines use and older age to benzodiazepines/barbiturates use. 
The comparison of results from urine and hair testing confirmed the complementary 
features of these two biological substrates and the importance to have both data in 
order to increase the sensitivity in detecting illicit drug use. Moreover, this study 
showed that testing for driving fitness is an effective deterrent to illicit drug use, as only 
about one quarter of subjects testing positive at the first testing are still positive at the 
second testing.  
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3. INTRODUCTION 
 
Traffic crashes are a common cause of death in many countries. Among the numerous 
risk factors (e.g. speed, talking on cell phones, road infrastructures), the effects of 
illegal drugs have an important role.  
Driving a motor vehicle is a necessary daily activity for many people, and it is a 
complex multifunctional task involving visual search and recognition, vigilance, 
information processing under variable demand, decision-making, risk taking and 
enough sensory-motor control to carry out all these activities correctly. It is believed 
that an ever-increasing number of people might be driving under the influence of illegal 
drugs (DUI), which would mean a high-risk factor in terms of road safety [1]. 
In the last few years the relation between illegal drugs and driving has been a subject 
of growing interest.  
A large body of literature demonstrates that the abuse of illicit drugs and alcohol is one 
of the main causes of the most serious road accidents [2,3,4]. In fact, use of narcotic 
and psychoactive drugs may impair driving skills, in respect of their effects on the 
central nervous system, by affecting alertness, visual acuity, reaction time, judgment 
and decision making, and so on [5,6]. 
 
3.1 EFFECTS ON DRIVING PERFORMANCE OF CONTROLLED 
DRUGS OF ABUSE 
 
MORPHINE: 
Morphine produces its major effects on the CNS primarily through -receptors, and 
also at -receptors and -receptors. receptors are involved in pain modulation, 
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analgesia, respiratory depression, miosis, euphoria, and decreased gastrointestinal 
activity.  
Effects on Driving: 
Drug manufacturers state that morphine may impair the mental and/or physical abilities 
needed to perform potentially hazardous activities such as driving a car, and patients 
must be cautioned accordingly.  
In several driving under the influence case reports, where the subject tested positive for 
morphine and/or 6-acetylmorphine, observations included slow driving, weaving, poor 
vehicle control, poor coordination, slow response to stimuli, delayed reactions, difficulty 
in following instructions, and falling asleep at the wheel. 
Miosis might be a cause of impaired vision at the entrance of a tunnel or when passing 
from light to shadow, as the eye is not able to rapidly adapt to the lower amount of light 
by dilating the pupil. 
 
METHADONE:  
Methadone is a long acting  opioid receptor agonist with potent central analgesic, 
sedative, and antitussive actions. Methadone inhibits ascending pain pathways, alters 
perception of and response to pain (dissociative effect), and produces generalized 
CNS depression.  
Effects on driving:  
Drug manufacturers caution that methadone may impair the mental and/or physical 
abilities required for the performance of potentially hazardous tasks, and that the 
sedative effects of the drug may be enhanced by concurrent use of other CNS 
depressants, including alcohol. Numerous European studies of long-term methadone 
maintenance patients have shown that appropriately administered methadone does not 
cause significant psychomotor or cognitive impairment when administered regularly 
and when the subject abstains from all other drugs. However, in the majority of cases, 
patients did not exhibit stable abstinence from drug use and had an increased 
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occurrence of simultaneous psychiatric/neurotic disorders or personality disturbances 
which, by themselves, could be a reason to doubt their driving ability. 
 
COCAINE: 
Cocaine is a strong CNS stimulant that interferes with the reabsorption process of 
catecholamines, particularly dopamine, a chemical messenger associated with 
pleasure and movement. Cocaine prevents the reuptake of dopamine by blocking the 
dopamine transporter which leads to increased extracellular dopamine, resulting in 
chronic stimulation of post-synaptic dopamine receptors. This results in the euphoric 
“rush”. When dopamine levels subsequently fall, users experience a dysphoric “crash”. 
Effects on Driving: 
Observed signs of impairment in driving performance have included subjects speeding, 
losing control of their vehicle, causing collisions, turning in front of other vehicles, high-
risk behavior, inattentive driving, and poor impulse control. As the effects of cocaine 
wear off, subjects may suffer from fatigue, depression, sleepiness, and inattention. In 
epidemiology studies of driving under the influence cases, accidents, and fatally injured 
drivers, between 8-23% of subjects had cocaine and/or metabolites detected in their 
blood.  
 
METHAMPHETAMINE AND AMPHETAMINE: 
Methamphetamine increases synaptic levels of the neurotransmitters dopamine, 
serotonin, (5-HT) and norepinephrine, and has  and adrenergic agonist effects. 
Norepinephrine is responsible for methamphetamine’s alerting, anorectic, locomotor 
and sympathomimetic effects; dopamine stimulates locomotor effects, psychosis, and 
perception disturbances; and 5HT is responsible for delusions and psychosis.  
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Effects on Driving: 
Drug manufacturers state that patients should be informed that methamphetamine and 
amphetamine may impair the ability to engage in potentially hazardous activities such 
as driving a motor vehicle. In epidemiology studies drive-off-the-road type accidents, 
high speed, failing to stop, diminished divided attention, inattentive driving performance 
would also be expected during drug withdrawal. Driving and driver behaviors included 
speeding, lane travel, erratic driving, accidents, nervousness, rapid and non-stop 
speech, unintelligible speech, disorientation, agitation, staggering and awkward 
movements, irrational or violent behavior, and unconsciousness. Impairment was 
attributed to distraction, disorientation, motor excitation, hyperactive reflexes, general 
cognitive impairment, or withdrawal, fatigue and hypersonnolence. 
 
METHYLENEDIOXYMETHAMPHETAMINE (MDMA, Ecstasy): 
MDMA is a phenylethylamine that has stimulant as well as psychedelic effects. MDMA 
is related in structure and effects to methamphetamine, however, it has significantly 
less CNS stimulant properties than methamphetamine. MDMA has a high affinity for 5-
HT2 receptors. The MDMA metabolite, S-(+)-MDA, destroys serotonin-producing 
neurons which play a direct role in regulating aggression, mood sexual activity, sleep, 
and sensitivity to pain. 
Effects on Driving: 
In an advanced driving simulator study, subjects were given a mean single dose of 56 
mg MDMA. Compared to a sober state, moderate effects on vehicle control, 
acceptance of higher levels of risk, acute changes in cognitive performance, and 
impaired information processing ability were observed. 
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CANNABINOIDS: 
Δ9-Tetrahydrocannabinol (THC) binds to cannabinoid receptors and interferes with 
important endogenous cannabinoid neurotransmitter systems. Receptor distribution 
correlates with brain areas involved in physiological, psychomotor and cognitive 
effects. 
Effects on Driving: 
Epidemiology data from road traffic arrests and fatalities indicate that after alcohol, 
marijuana is the most frequently detected psychoactive substance among driving 
populations. Marijuana decreased car handling performance, increased reaction times, 
impaired time and distance estimation, inability to maintain headway, lateral travel, 
subjective sleepiness, motor incoordination, and impaired sustained vigilance have all 
been reported. Mixing alcohol and marijuana may dramatically produce effects greater 
than either drug on its own. 
 
BENZODIAZEPINES: 
Benzodiazepines bind with high affinity to the GABAA receptor in the brain to 
reduce arousal and to affect emotions.  
Effects on Driving:  
The drug manufacturer suggests patients treated with benzodiazepines be cautioned 
against engaging in hazardous occupations requiring complete mental alertness such 
as driving a motor vehicle. Use of benzodiazepines can increase lateral deviation of 
lane control, reduce reaction times, reduce ability to perform multiple tasks, decrease 
attention, adversely effect memory and cognition, and increase the effects of fatigue. 
Significant impairment is further increased when benzodiazepines are combined with 
low concentrations of alcohol. 
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3.2 DIAGNOSIS OF DRIVING FITNESS WITH REFERENCE OF 
DRUG ABUSE ACCORDING TO THE ITALIAN ROAD CODE 
 
The diagnosis of driving fitness in relation to the use of narcotic drugs and psychotropic 
substances is regulated in our country by Article 119 (“physical and psychological 
requirements for obtaining a driving license”) of Legislative Decree No. 285 of 30 April 
1992 (better known as “Nuovo Codice della Strada”) [7] and subsequent amendments 
and additions, and Art. 319 and 320 of its implementing Regulation (DPR 495/1992 and 
subsequent amendments and additions) [8].  
According to the laws presently in force in Italy, the driving license must not be issued 
neither confirmed to anyone who abuses, is addicted to, or suffers for dependence 
from alcohol and illicit or psychotropic drugs which may impair her/his driving ability. 
The evaluation of these conditions is carried out by a specific medical commission of 
the Public Health Service set up in each province, on the basis of clinical and 
laboratory tests, whose cost is borne to the user applying for the issue or renewal of 
driving license. It should be clarified, in this regard, that on one hand the local medical 
commissions have broad freedom of action as to the criteria for diagnostic evaluation; 
on the other, users have the possibility of choosing the local medical commission 
where to undergo the diagnostic evaluation. 
Among the individuals who are required to undergo this evaluation are: subjects sent 
by the prefect or by the office of the department responsible for land transportation, 
those for which the medical doctor examination requires toxicological test to assess the 
fitness to drive, as well as subjects tested positives for alcohol and drugs of abuse at 
road-side testing (Art. 186 and 187 CdS). 
A recent change in Art. 119, in force since 13th august 2010, also requires preventive 
toxicological examinations for the first issue of the driving license and for workers 
assigned to duties which may endanger public safety [9]. 
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As regards workers employed in duties that may imply a risk to security, safety and 
health of their own and third parties, the diagnosis of drug addiction or of sporadic use 
of drugs is achieved, in accordance with the provisions of the Conferenza Unificata 
Stato-Regioni e P.A. of 30 October 2007 [10], by means of a clinical exam including 
the testing of  itself of an urine specimen collected from the employee after a 
notification time not exceeding 24 hours [11]. 
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4. AIM OF THE STUDY 
 
The Forensic Toxicology laboratory, Section of Forensic Medicine, Department of 
Public Health and Community Medicine, University of Verona, exclusively performs 
clinical and analytical toxicological investigations on subjects sent by the Medical 
Commission of the Province of Verona. In particular, each subject is submitted to a 
clinical examination, to an interview for the collection of anamnestic and clinical data 
and to the collection of biological samples (urine and/or hair) for drugs of abuse testing.  
The amount of data collected so far (an average of 160 new subjects per year to which 
are to be added subjects who were requested to undergo subsequent examinations 
after the suspension/validity period of their driving license was expired) has led us to a 
thorough examination of the data collected in recent years (2003-2008).  
Although other authors have previously ventured into the development of statistical and 
epidemiological case studies relating to ascertainment of fitness to drive in relation to 
the use of drugs [12-15] with the aim of evaluating the relative frequency of positivity 
for different classes of drugs of abuse and any trend of these frequencies, our study 
intended to investigate, in addition to the aspects just mentioned, also the evaluation of 
possible risk factors for testing positive and for relapse and the comparison of the 
effectiveness of different diagnostic established approaches. 
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5 MATERIALS AND METHODS 
 
The survey was conducted on the requests for control of the use of narcotic and 
psychotropic substances sent by the Local Medical Commission (C.M.L) of Verona to 
our laboratory for the purpose of diagnosis of driving fitness within the period 2003-
2008. Based on these request, we proceeded to summon the people for carrying out 
clinical examination and biological sampling. For most of the statistical and 
epidemiological process only the first check was taken into account with the inclusion 
of checks after the first only for specific purposes.  
During the period under study the requests received from the C.M.L. were 981 and 
corresponded, in the vast majority of cases, to one of the following types: 
 
- Drivers tested positive for driving under the influence of drugs  
- Drivers to whom the driving license had been suspended/withdrawn because 
they were found positives to drug testing after a car accident 
- Subjects dependent on public or private facilities for the care and rehabilitation 
of drug use 
- Subjects to whom the driving license had been suspended following a report to 
the prefecture for use or possession of drugs  
 
5.1 SAMPLING PROTOCOL 
 
The type of sampling protocol (e.g. urine and/or hair) was established by the Medical 
Commission on the basis of the clinical records of the subjects. 
The adopted protocol consisted in the collection of clinical and anamnestic data and 
urine and/or hair samples. In particular, the protocol for urine collection consisted either 
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in 3 urine samples randomly collected without notice to the subjects within a 4-week 
period or in 8 urine samples collected at pre-defined times with notice to the patient 
within the same period of time. The first urine protocol was adopted only in the 4% of 
the case, the second was more common and was carried out on the 96% of the 
subjects. 
In the case of hair analysis, a single hair sample (3-4 cm proximal segment in order to 
infer on the history of drug use during the 3-4 month period preceding sample 
collection) was collected at the beginning of the sampling protocol. Personal as well as 
clinical and anamnestic data on the individuals undergoing urine and or hair analysis 
were recorded together with test results in a database constructed using Microsoft 
Access (Version 2003). The subsequent statistical elaboration was performed with 
Microsoft Excel (Version 2003) and software PSPP (Version 0.6.2). 
 
5.2 CHEMICALS AND REAGENTS 
 
Pure standards of morphine, codeine, 6-monoacetylmorphine (6-MAM), 
dihydrocodeine, methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), 
cocaine, benzoylecgonine, cocaethylene, ecgonine methyl ester, amphetamines (A), 
methamphetamine (MA), 3,4-methylenedioxyamphetamine (MDA), 3,4-
methylenedioxymethamphetamine (MDMA), N-methyl-1-(1,3-benzodioxol-5yl)-2-
butamine (MBDB), methylenedioxyetamphetamine  (MDE) and 11-nor-9-carboxy-Δ9-
tetrahydrocannabinol (Δ9-THC-COOH) were purchased from S.a.l.a.r.s. S.p.a. (Como, 
Italy). Benzodiazepines (bromazepam, clobazam, chlordesmethyldiazepam, diazepam, 
flunitrazepam, flurazepam, lorazepam, lormetazepam, medazepam, nitrazepam, 
nordazepam, oxazepam, temazepam) and barbiturates (fenobarbital and butalbital) 
were obtained from commercial drugs. 
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N-methyl-N-trimethylsilyl-trifluoroacetamide (MSTFA) was purchased from Sigma (St 
Louis, Italy), -glucuronidase was also purchased from Sigma. 
TWEEN was purchased from A.C.E.F. S.p.a., (Fiorenzuola d’Arda (PC), Italy). The 
bidistilled water used throughout the present study was obtained from an aqua MAX-
Ultra 370 Series water purification system (Young Lin Instrument, Anyang, Korea). 
Solvents and reagents (HCl, NaOH, monobasic phosphate) of C. Erba, Milan, Italy 
were reagent grade.  
Bond Elut Certify LRC cartridges (10 ml capacity, 130 mg) and C18 cartridges (6 ml 
capacity, 100 mg) were obtained from  Agilent (Santa Clara, CA, USA). Toxi-Tube B 
from Varian (Harbor City, CA, USA). 
 
5.3 IMMUNOCHEMICAL SCREENING 
 
Urinary screening was performed with CEDIA MULTI-DRUG kits (Microgenics 
Corporation, Fremont, CA, USA), after sample centrifugation (3500 rpm, 10 min), for 
the following substances: opiates, methadone, cocaine, amphetamines and 
metilendioximethamphetamines, cannabinoids, benzodiazepines and barbiturates. Hair 
samples (100 mg) were washed with 3 % TWEEN solution in water, thoroughly rinsed 
with water and then were manually cut into small fragments and incubated overnight in 
1 ml of HCl 0.1 M at 45°C. The resulting mixtures were neutralized with NaOH 0.1 M 
and screened for opiates, cocaine and amphetamines and derivates using the CEDIA 
kits for urine adapted. 
The adopted cut-off for urine screening was 500 ng/ml for amphetamines and 
derivates, 300 ng/ml for opiates, methadone and benzoylecgonine, 200 ng/ml for 
benzodiazepines and barbiturates and 50 ng/ml for cannabinoids in agreement with 
those provided by the commission of the group of Italian Forensic Toxicologists (GTFI). 
Positives samples in the keratin matrix screening were reported when the 
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concentration values were above 10 ng/ml for opiates and cocaine and 25 ng/ml for 
amphetamines and derivates corresponding to a concentration of 0.1 ng/mg and 0.25 
ng/mg in keratin matrix. 
 
5.4 CONFIRMATION ANALYSIS 
 
Confirmation analysis for both matrices was carried out by gas chromatography/mass 
spectrometry (GC-MS) after solid-phase extraction (SPE) and silyl-derivatization. 
For urine, solid-phase extraction cartridges was performed with a mixed mode 
extraction 130 mg Bond Elut Certify for analytes predominantly alkaline and C18 
cartridges of 100 mg for cannabinoids. The eluates were evaporated to dryness under 
air stream on hot plate at 65°C, the residues were reconstituted with 50 l of N-metil-N-
trimetilsililtrifluoroacetamide (MSTFA) and examined by GC-MS by monitoring 3-4 
specific ions in Selected Ion Monitoring (SIM) mode. 
Subjects screened positives for benzodiazepines and barbiturates were confirmed only 
if the use was not declared by the user during the clinical examination. The 
determination of total benzodiazepines was made through liquid-liquid extraction with 
butyl acetate at alkaline pH after hydrolysis with -glucuronidase while the 
determination of barbiturates was made with a liquid-liquid extraction using Toxi-Tube 
B. Cut-off values used for confirmation analysis were 100 ng/ml for each substances 
detected, except for cannabinoids and amphetamines and derivates which have cut-off 
respectively of 250 ng/ml and 30 ng/ml.  
The confirmation analysis in hair, by GC-MS, was preceded by a solid phase extraction 
(Bond Elut Certify cartridges 130 mg) for the three classes of substances after addition 
of 1 ml of 0,1 M phosphate buffer at pH 6-7 on the incubation mixtures obtained as 
described above. In this case a sample was considered positive when the 
concentration of drugs of abuse was above the cut-off of 0,1 ng/mg. 
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The GC-MS system used, consisted of an Agilent Model 6850 gas chromatograph 
equipped with a Model 5975C mass-selective detector (Agilent Technologies, Santa 
Clara, CA, USA). The column used (Agilent Technologies, Santa Clara, CA, USA) was 
a fused silica capillary column (HP-5 fused-silica capillary column, 30m x 0,25 mm I.D., 
0.25 m film thickness cross-linked 5% phenyl-methylsiloxane). Helium was used as 
the carrier gas at a constant flow-rate of 1 ml/min. The injector operated in the pulsed-
splitless mode at 250°C and the injection volume was 1 l. Initial oven temperature was 
100°C, maintained for 1 min, increasing (30°C/min) at 200°C and followed by a ramp at 
a rate of 15°C/min to 290°C and maintained at this temperature for 7 min. 
Identification criteria were based on the retention time ± 0.02 min with respect to the 
same criterion in the spiked hair sample and on the relative abundance of the three 
confirming ions with respect to the target. Quantitative data were obtained by selected 
ion monitoring for each compound and for internal standards. Monitored ions and the 
retention time for each compound are shown in [Table 1]. 
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[Table 1] Selected ions and retention times. 
 
Compound Rt (min)a Ion m/z 
Morphine 10.35 429, 401, 414 
Codeine 10.09 371, 313, 343 
6-MAM 10.70 399, 340, 287 
Dihydrocodeine 9.74 373, 236, 282 
Methadone 8.41 72, 178, 294 
EDDP 7.89 277, 276, 220 
Cocaine 8.74 182, 82, 303 
Benzoylecgonine 9.09 82, 240, 346 
Cocaethylene 9.04 82, 196, 272 
ecgonine methyl ester 5.30 82, 96, 240, 271 
A 4.02 116, 91, 192 
MA 4.42 130, 91, 206 
MDA 5.46 116, 135, 236 
MDMA 5.79 130, 250, 91 
MBDB 6.30 144, 264, 135, 73 
MDE 6.09 144, 264, 135 
Δ9-THC-COOH 5.88 371, 473, 488, 489 
 
Quantifier ion in bold 
a Retention time ± 0.02 min 
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6. RESULTS AND DISCUSSION 
 
In the period under study, from 2003 to 2008, more than a quarter of subjects didn’t 
show up after being called upon for clinical examination and samples collection. Among 
the remaining, 231 subjects tested positive for one or more than one substances in 
urine and/or hair (24% of the total number, 32% of the subjects analyzed) and 483 
subjects tested negative (49 % of the total, 68 % of the subjects analyzed). 
We observed a progressive increase of request for investigations: from 152 in 2003 to 
187 in 2008; with an increase of approximately 23%. 
The time course of the percentage of people positive for one or more drugs of abuse 
respect to request for investigation was fluctuating between 20% and 30% and 
characterized by a modest decline in the last year considered [Fig. 1]. 
 
 
 
[Fig. 1] Time course of the frequency of positivity for different classes of drugs of 
abuse. 
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The positivity rate of subjects tested, ranged from 30% to 40% with the exception of 
2008, the year in which there was a substantial decline (approximately 20% positivity). 
Cocaine, 17% (n=124), was the drug most frequently detected, followed by 
cannabinoids 12% (n=86), benzodiazepines 6% (n=42), opiates 3% (n=22), 
amphetamines and derivates 3% (n=21), methadone 3% (n=21) and barbiturates 1% 
(n=5). Thirty percent of the subjects who tested positives, were positives for more the 
one drug class, and one of these was usually cocaine. The most frequent combination 
was cocaine plus cannabinoids. 
The time course of positivity for different classes of substances was relatively constant 
for opiates, methadone, amphetamines and barbiturates, cocaine and cannabinoids 
have shown a more fluctuating trend with a significant increase of positivity in 2007 but 
was not confirmed in the next year where there was a decline of the subjects tested 
positive for all the substances [Fig. 2]. 
 
 
 
[Fig. 2]  Drug classes detected over the years. 
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The request for investigation were mostly to male subjects (n=907, 93%). However, 
over the years, was found a steady increase of request for investigation to female 
subjects (from 5% in 2003 to 11% in 2007) to which is also corresponded an increase 
of positivity. However, this trend was not confirmed in 2008 when there was a decline 
both of percentage of request (6%) and of percentage of female subjects tested 
positive (1%). No relevant difference in the distribution of drug classes detected in the 
two genders was observed [Fig. 3]. 
 
 
 
[Fig. 3] Distribution of positivity for different classes of drugs between males and 
females. 
 
The mean age of the subjects analyzed was 31±8 years (median, 30 years) and was 
almost the same for the subjects who didn’t show up for the clinical examination (32±8 
years). Nevertheless, the age range was wider in the first group (18-63 and 18-52 
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respectively). Mean ages very similar were also observed between positive and 
negative subjects (31±8 years and 31±9 years respectively). 
Instead different mean ages were observed among subjects testing positive for 
different drug classes: benzodiazepines > barbiturates > opiates > cocaine = THC 
>amphetamine [table 2]. 
 
[Table 2] Age (in years) of the users tested positive the different classes of 
substances. 
 
 
 
In particular, younger subjects, with a mean age of 23 years, seem to have a higher 
risk to use amphetamines while older subjects, with a mean age of 35/36 years, are 
more frequently exposed to benzodiazepines and barbiturates. This difference was also 
significant (P<0,001).  
Nearly 10% of requests for investigation were from subjects of foreign nationality 
(n=94). 95% residing in the Province of Verona (n=929), one quarter of which was a 
resident in the centre of Verona (n=233). The comparison between positive and 
negative in relation to place of birth, and residence (city of Verona, Verona Province, 
Veneto and other regions, foreign countries) did not show considerable differences, 
highlighting that these factors do not significantly change the likelihood of a positive 
finding. 
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Among smokers, who represent approximately the 91% (n=543) of the subjects 
analyzed, and among subjects with an anamnesis for alcohol-abuse (17 %, n=121) it 
was possible observe a greater frequency of positive: 33% and 23% positivity in 
smokers and non smokers, 35% and 31% between subjects with or without a history of 
alcohol abuse, respectively. However, the sample size does not seem sufficient to 
show a possible statistical significance; only between smokers and not smokers we 
observed a chi square: P = 0,14. 
The same analysis carried out on non drinkers and coffee drinkers highlighted that 
among the subjects who doesn’t drink coffee (8.2%; n=36, of the subjects for which 
that information was available), the positivity for drugs of abuse is more common (44% 
versus 31% positivity among coffee drinkers). However, also in this case, the observed 
difference was not supported by statistical significance.  
67.4% (n=475) of the subjects analyzed, has a normal body mass index 
(18.5<BMI<24.9), while just under one third are overweight or obese (BMI>24.9, 30.4% 
n=214) and 2.3% (n=16) is underweight (BMI<18.5). The BMI distribution between 
subjects positive and negative is essentially comparable with regard to the classes of 
normal weight (68% between positive, and 67.1% between negative) and 
overweight/obese (28.9% between positive, 31% between negative) with a more 
marked difference with regard to individuals underweight. The BMI distribution among 
subjects tested positive for different drugs classes shows that subjects 
overweight/obese are less represented among positives for cocaine and THC, while 
overweight subjects are more frequent between positives for opiates and 
benzodiazepines [Fig. 4]. 
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[Fig. 4] Distribution of BMI for different drug classes. 
 
This observation appears to be correlated to the mean age of subjects tested positives 
for the different drug classes [Table 2]. In other words, the higher BMI in subjects tested 
positive for opiates and benzodiazepines may be justified by the increased mean age 
of the subjects positive for these substances and, therefore, by the physiological gain in 
weight that occurs with age [16]. Therefore, in order to isolate the effect of BMI from 
age, subjects tested positive for each class of substances have been further broken 
down into three age groups: 18-25 years, 26-35 years and >45 years [Fig. 5]. 
This analysis showed, as expected, an overall increase in BMI with age in both 
subjects tested positives and negatives, but also other interesting observation. In 
opiates and amphetamines users the increase of BMI with age was much more marked 
than in negatives. Instead, in cannabinoids users, the curve differs from that of 
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negative subjects in the second half, while for cocaine and benzodiazepines users, the 
BMI trend was approximately the same of negatives [Fig. 5].  
 
 
 
[Fig. 5] Variation in body mass index (BMI) for different classes of drugs of abuse                  
in relation to the age. 
 
The statistical comparison (Student’s t-test) between positive for each class of 
substances and negative within each age group did not differ significantly, with the 
exception of cannabinoids users in the age >36 years, which are characterized by an 
average BMI lower than of negatives in the same age range (P=0,005). 
Not unlike what is found in the general population, the female gender, of the subjects 
analyzed, tends to have a BMI lower (the percentage of overweight corresponds to 
21% and 31% among females and males respectively). Interesting was to observe a 
lower BMI among females tested positive respect to negative (with a difference at the 
limit of the statistical significance, P=0,07) compared to a substantial overlap between 
the distributions of BMI in positives and negatives males. Therefore, it can be 
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concluded that the greater proportion of underweight subjects observed in the overall 
sample of positives respect to negatives is mainly due to female gender. 
The data of systolic and diastolic blood pressure recorded at the time of the clinical 
examination were used to make a classification of blood pressure according to what is 
proposed by the Italian Society of Hypertension [17]. In particular, the systemic blood 
pressure was classified considering the highest class between systolic and diastolic 
pressure. Since clinical examination is carried out away from any acute episode (e.g. 
driving under the influence of drugs) the data of blood pressure may be related to 
possible chronic consequences of the assumption or simply to a condition of stress 
related to the investigation, particularly by those who fear a positive test results. The 
analysis of the data seems to support the latter hypothesis because among positives 
appears to be a higher rate of subjects with mild hypertension compared to negatives 
(P=0,11675). This difference is approaching to statistical significance by excluding 
positive for benzodiazepines (P=0.0659) [Fig. 6]. 
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[Fig. 6] Distribution of blood pressure for users, respectively, positive and 
negative to the toxicological investigation. 
 
The distribution in age groups shows that the difference is statistically significant only 
for the age group 18-25 years (P=0.0609, including benzodiazepines, P=0.0389 
excluding benzodiazepines). Is also interesting to note that, from the breakdown by 
class of substances, the greater frequency of cases of mild hypertension is observed 
between positives to cocaine (P=0.0123), while for the other classes the difference are 
far from a statistical significance. 
About 1 in 10 subjects analyzed declared the positivity to HBV (3%) and/or HCV (11%) 
and/or HIV (2%). The distribution of singularly or combined positivity in the outcome of 
the investigation showed a lower rate of positivity for drugs of abuse in subjects 
positives for one of these marker. This difference, which is approaching to statistical 
significance (Chi-Square, P=0.09), however, appear significantly affected by the lack of 
specific question in medical records related to the positivity or negativity to these 
markers. This allowed us to detect only positive self-declaration, but it was not possible 
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to distinguish between negative to these markers and missing data. The statistical 
evaluation could therefore show a greater tendency to hide this information from the 
subjects tested positive, rather than a “protective effect” due to the presence of one of 
these infections.  
The medical record contained a question on the subject’s involvement in road 
accidents or work accidents, in a state of intoxication or withdrawal. Was observed a no 
significantly higher frequency of previous accidents among those had a positive results 
(15% versus 11% among negative, P=0.25). However in doubt that the answer to these 
question could include the road accident that led to the call for the examination, 
becoming an obvious confounding factor, the analysis was repeated excluding all 
cases in which appeared a car accident as the reason for the call. In fact, the largest 
proportion of cases with previous accidents among positives remains although smaller 
(7% vs. 5% of negatives). The breakdown of the data for classes of substances  
reveals a higher frequency of previous accidents among positives for benzodiazepines 
(12%), opiates (10%) and cocaine (7%), while for cannabinoids (3%) and 
amphetamines (0%) the frequency was lower than negatives. 
The toxicological anamnesis (previous use of one or more than one drugs or 
psychotropic substances) appears in many cases useful to have ideas on the present 
use of drugs by the subjects [Table 3]. Even though in about one third of cases the self-
declaration of previous use of drugs match with the test results (with a rate of positivity 
of 32% among cases with a positive anamnesis and 30% among cases with a negative 
anamnesis) high differences are found separating the anamnestic data into classes of 
substances. 
In particular, was observed that a positive anamnesis for cocaine increased 
significantly (Chi-square, P=0.004) the probability of a positive outcome of the 
investigation for any substance (the P value increases to 0.006 excluding positive for 
benzodiazepines). Instead the positive anamnesis for amphetamines or opiates or 
cannabinoids has no predictive value of the outcome of the investigation. Only in the 
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case of a positive anamnesis for opiates there is a nearly significantly lower rate of 
positive subjects for any substances (P=0.068 excluded benzodiazepines). Positive 
anamnesis for a class of drug of abuse appears in all cases significantly increase the 
probability of positivity for the same class of substances (Chi-square: cocaine, 
P<0,0001; opiates, P<0,0001; amphetamines, P<0,0001; cannabinoids, P=0,012; 
benzodiazepines, P<0,0001). In particular was found that 25% of subjects who 
reported a previous use of cocaine, were than actually positive for this substances, 
while the corresponding percentages for opiates, amphetamines and cannabinoids are 
respectively, 8%, 10%, 13%. 
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Therefore, the proportion of subjects tested positive for the same class of substances 
which reported during the clinical examination, can be used as an indicator of the 
truthfulness of the statement provided by the subject. This proportion appears to be 
higher among positive for cannabinoids (85%) followed by positive for opiates (68%), 
cocaine (52%) and amphetamines (43%) [Fig. 7]. 
 
 
 
[Fig. 7] Percentages of subjects tested positive for a class of drugs of abuse that 
had declared the use of the substance before the investigation. 
 
Part of the research was dedicated to assessing the possible correlation between the 
outcome of the investigation for drugs of abuse (performed, as previously reported, on 
subjects in almost all cases, residents in the province of Verona) and data on road 
accidents occurred on the provincial area [18] [Table 4]. 
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A first comparison regarded the percentage of positivity and the number of road 
accidents in relation to the car fleet circulating in the province. Effectively, between the 
two parameters, there was a positive trend: with the growth of positivity was observed a 
progressive increase in the rate of car accidents. However, the coefficient of linear 
regression is small (R2=0.197). If we substituted the accident rate with the rate of fatal 
accidents, the modest correlation disappears (R2=0.009), while it increase slightly 
considering the number of injured per accident in relation to the car fleet circulating 
(R2=0.226). More detailed information were obtained comparing the accident rate, with 
the frequency of positives decomposed into different classes of substances. In 
particular there was no correlation with regard to amphetamines and benzodiazepines, 
however, there was a better correlation with regard to the frequency of positivity for 
cannabinoids, cocaine and in particular for opiates in relation both to the accident rate 
(R2=0.343, 0.347 and 0.779, respectively) and the number of injured per accident, 
compared to the car fleet circulating (R2=0.337, 0.415, and 0.786, respectively). In 
relation to the frequency of fatal accident, positive trends were observed for 
cannabinoids (R2=0.050), cocaine (R2=0.186) and opiates (R2=0.489), although only in 
the last case, the regression coefficient is of some importance. Since the Italian Road 
Code (Art. 187), requires obligatory toxicological test after a car accident, and the 
positive individual to these test is submitted to a clinical examination aimed at 
evaluating his/her fitness to drive (Art. 119 CdS), it can be argued that the positive 
trend observed between subjects tested positive and the number of car accident are 
due to the fact that if increases the number of accidents, so also increases the number 
of controls. However, this hypothesis is contradicted by the fact that during the period 
under studying, there is no positive trend between the absolute number of traffic 
accidents and number of checks required by Art.119 (visits for fitness to drive). 
Part of the research was dedicated to evaluating the effectiveness of the investigation 
carried out in urine or hair. To this aim were considered the subjects for which the 
C.M.L. has requested both matrices (n=885, 90% of the subjects; n=628, 67% 
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excluded the subjects who didn’t show up for the examination). Since the investigation 
on hair was only for opiates, cocaine and metabolites and amphetamines, the 
comparison was limited to these substances. In the case of urine, although we used 
two different protocols (see materials and methods), the protocol based on 3 urine 
samples randomly collected without notice to the subjects was applied in a small 
minority of cases (4%) therefore it was decided to carry out statistical analysis without 
breaking down for urine protocol. A first important result, which is largely confirmed in 
the literature [19] is that a determination on keratin matrix appears with a greater 
epidemiological sensitivity than urine matrix, although with interesting differences 
between the different classes. Indeed, while the difference in sensitivity is low in the 
case of opiates (0.68 against 0.55) becomes significantly higher for cocaine and 
metabolites (0.91 against 0.25) and amphetamines (0.86 against 0.14). This 
observation could be at least partly related to the different time windows of detection in  
urine matrix (generally greater in the case of opiates) and/or a greater tendency of 
opiates to determine a depending resulting in frequent use [20]. Furthermore, the urine 
protocol has shown its utility, since for all classes of substances there were subjects 
tested positive exclusively in urine (8% for cocaine, 14% for amphetamines and 32% 
for opiates). This confirm the complementary nature rather than alternative of the two 
biological matrices. 
Apart of the outcome of the investigation and the diagnosis of fitness to drive by the 
C.M.L. all subjects underwent a further analysis after a variable period of time, usually 
determined by the diagnostic evaluation of the first check (greater interval for negative 
subjects) 
Therefore it was considered useful to undertake a valuation of the outcome of the 
second check in relation to the first, in order to determine whether and how the 
suspension of the driving license, and the consequences that this implies on social and 
professional level, is an effective deterrent to drug use. The answer to this question is 
positive, since just over a quarter (27%) of cases positivity at the first check was 
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followed by a positive result at the second check. Also in this case the breakdown by 
classes of substances reveals interesting differences [Table 5]. 
 
[Table 5] Analysis of positivity at the II°check 
 
 
 
In fact, positivity at the second check are more frequent among subjects who tested 
positive at the first check for opiates and amphetamines (43% and 46% respectively) 
followed by cannabinoids and methadone (34% and 33% respectively) and a greater 
distance by cocaine. Moreover within the different classes of substances there are 
marked differences with regard to fidelity to the substance found in the first analysis. In 
fact if, for example, the positivity at the first check for opiates, methadone and cocaine, 
is confirmed in almost one case out of two, and in two out of three for cannabinoids, in 
the case of amphetamines, the second check reveals a percentage of positives less 
than 20%. Also the time period between the first and the second check seems to 
influence the percentage of positives at the second. In fact, it tends to decrease with 
the increasing of this range (34% within 6 months, 25% between 6 and 12 months). 
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7. CONCLUSIONS 
 
The analysis of cases presented offered many points of interest and reflection. First, 
results confirm the complementary nature of the information provided by the analysis of  
hair and serial urine, since each of the two analytical strategies applied individually 
leads to a significant reduction in the epidemiological sensitivity of the investigation. It 
is also interesting to note that several associations between "risk factors" and testing 
positive for any drug of abuse (i.e. BMI<18,5, smoking, not drinking coffee, mild 
hypertension and, of course, a previous history of drug abuse) or for one or more 
classes/specific substances (e.g. young age and amphetamines, mild hypertension and 
cocaine, BMI and THC). For some of these factors, the observed difference between 
positives and negatives, although approaching statistical significance, does not reach it 
and will therefore be interesting to verify their effective role on a larger amount of data. 
The comparison between self-reports of illicit drug use and urine/hair testing results 
shows that the reliability of self-report decreases in the following order: 
THC>opiates>cocaine>amphetamines. 
An interesting outcome that deserves a further development is the possible relation 
between the number of opiates positives and the rate of car crashes observed in  
corresponding years. 
In addition, and this is probably the most relevant and reassuring outcome of our study, 
it is clear from the comparison between first and the second check on the same 
subject, that the chance of being diagnosed as unfit for driving as a consequence of 
testing positive for drugs of abuse exerts a substantial deterrent effect on their 
consumption. In other terms, it is evident that possessing a driving license plays a 
crucial role both professionally and socially speaking, and avoiding the risk of not 
getting it back is likely considered a valid return to abstaining from illicit drugs. 
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A final consideration refers to the large number of subjects who didn’t show up for the 
clinical examination requested by the C.M.L., representing over one quarter of the total 
requests. This phenomenon might, at least partially, be explained by the chance for the 
subject to decide to which Medical Commission to apply for the diagnosis of driving 
fitness.  As a consequence, the adoption of less restrictive diagnostic criteria by C.M.L. 
of geographic areas close to the province of Verona might be a reason for diverting 
from the Verona C.M.L.. For example, the cut offs adopted for drug testing in hair are 
generally higher in the C.M.L of Lombardy (e.g. 0.5 ng/mg for cocaine) than in the 
Veneto Region (0.1 ng/mg), providing the applicant a more than good reason for 
choosing a lombard C.M.L. Therefore, it will be interesting in perspective to cross-
check the databases of other proximal C.M.L. to estimate to what extent this 
phenomenon occurs.  However, the only possibility of this occurrence is a more than 
relevant motivation to invoke a rapid and appropriate standardization of the analytical 
and diagnostic criteria applied by the different C.M.L.. 
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